Refractory Chronic Cough Improvement Via NAL ER (RIVER)

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions
Refractory Chronic Cough
Interventions
DRUG

NAL ER

Oral tablets

DRUG

Placebo

Oral tablets

Trial Locations (14)

L8N 3Z5

McMaster University Medical Centre, Hamilton

M5T 3A9

Inspiration Research, Toronto

G8T 7A1

CIC Mauricie Inc., Trois-Rivières

HU16 5JQ

Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital, Cottingham

SE5 9RS

Kings College Hospital NHS Foundation Trust, London

M23 9LT

University Hospital of South Manchester NHS Foundation Trust (UHSM) - Wythenshawe Hospital, Manchester

BR5 3QG

Accellacare South London, Orpington

HA6 2RN

Accellacare North London, Northwood

BT9 7AB

Belfast City Hospital, Belfast

NE29 8NH

North Tyneside General Hospital - Northumbria Healthcare NHS Foundation Trust, North Shields

CV3 4FJ

Accellacare Warwickshire, Coventry

B15 2GW

University Hospitals Birmingham NHS Foundation Trust, Birmingham

BD18 3SA

Accellacare Yorkshire, Shipley

HP11 2QW

Egin Research Ltd, High Wycombe

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Trevi Therapeutics

INDUSTRY